Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

计划入组 13 人 · 首次发布于 2009 年 7 月 3 日

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

计划入组 500 人 · 首次发布于 2015 年 12 月 22 日

Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy

计划入组 11 人 · 首次发布于 2014 年 7 月 18 日

Peanut(Palforzia 12 Mg (level 3), Palforzia 120 Mg (level 7), Palforzia 160 Mg (level 8), Palforzia 20 Mg (level 4), Palforzia 200 Mg (level 9), Palforzia 240 Mg (level 10), Palforzia 3 Mg (level 1), Palforzia 300 Mg (level 11), Palforzia 40 Mg (level 5), Palforzia 6 Mg (level 2), Palforzia 80 Mg (level 6), Palforzia Initial Dose Escalation)

Peanut oil

IgE kinoid

DBV Technologies

France

Telix Pharmaceuticals

Australia

Repare Therapeutics

United States

Dupilumab Shows Limited Success in Peanut Allergy Desensitization Study

Omalizumab Approval and Media Impact Highlight Top Food Allergy Stories of 2024

PRT120 Peanut Oral Immunotherapy Demonstrates Durable 3-Year Remission in Phase 2b Study